Loading - Please Wait

Loading - Please Wait

Sophie: A Case Study in CF Management

Sophie, your 13-year-old patient, visits your office for her quarterly checkup. All of her evaluations show that not much has changed since her last visit. Sophie’s FEV1 is 92% and she is in the 50th percentile for height and weight. Sophie’s mother comments that Sophie is coughing more than before, although neither Sophie nor her mother is concerned by the symptom. What, if anything, should you do for Sophie now?

Sophie: A Case Study in CF Management is an interactive and engaging program, led by Patrick Flume, MD and Michael Schechter, MD. As you respond to selections during the program, faculty-led discussions respond with tips and techniques to optimize treatment.

Start / Register

Program Directors

Patrick Flume, MD

Professor of Medicine and Pediatrics
The Medical University of South Carolina
Powers-Huggins Endowed Chair for Cystic Fibrosis
Charleston, South Carolina



Patrick Flume is a Professor of Medicine and Pediatrics at the Medical University of South Carolina and has been part of the MUSC program since 1993. He serves as the Powers-Huggins Endowed Chair for Cystic Fibrosis and oversees a rapidly growing Cystic Fibrosis Center, including the largest adult CF program in South Carolina.

He is recognized by the national and international CF community having served on the CF Foundation Center Committee, the Adult Care Consensus Committee, and the Advisory Task Force on Adult Issues, the Professional Education Committee, the European CF Society’s Best Practices committee, and as founding co-chair of the CF Foundation’s Pulmonary Practice Guidelines Committee. He is the Deputy Editor for the Journal of Cystic Fibrosis.

His also leads a very busy clinical research program for CF. Many of these studies are related to new drug and therapy development for patients with CF, but he also has an interest in determining optimal management of pulmonary exacerbations and is the co-PI in the STOP trials, aimed at identifying optimal treatments for exacerbations.

Michael S. Schechter, MD, MPH

Professor and Chief, Division of Pulmonary Medicine
Department of Pediatrics
Virginia Commonwealth University
Children's Hospital of Richmond at VCU
Richmond, Virginia



Dr. Schechter is professor and chief of the Division of Pulmonary Medicine at the Children’s Hospital of Richmond at Virginia Commonwealth University and Director of the VCU Cystic Fibrosis Center.

Dr. Schechter’s research has focused on environmental and sociodemographic influences as well as the impact of treatment variations on outcomes in Cystic Fibrosis, and his investigative work has primarily involved secondary database analyses. He has also worked with the CF Foundation on fostering methods to improve the quality of care and outcomes for children with CF, and has participated in projects to improve the care of children with other chronic conditions such as Spina Bifida, Inflammatory Bowel Disease, Sickle Cell Disease, and Asthma.

Dr. Schechter has served on numerous committees of the Cystic Fibrosis Foundation, American Thoracic Society, and American Academy of Pediatrics, and is past chair of the AAP Section of Pediatric Pulmonology and Sleep.

CME/CE

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Educational Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty Disclosures

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Patrick Flume, MD: Consulting fees from Bayer Heathcare AG, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Horizon Pharma, Insmed, McKesson, Novartis, Proteostasis Therapeutics, Vertex Pharmaceuticals, Inc. Fees related to commercial interests: Bayer Heathcare AG, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Galapagos, Insmed, National Institutes of Health, Novartis, Novoteris, Proteostasis Therapeutics, Sound Pharmaceuticals, Inc., and Vertex Pharmaceuticals, Inc.

Michael S. Schechter, MD, MPH: Consulting fees from Vertex Pharmaceuticals, Inc. and commercial interest from Astra-Zeneca.

Launch Date: 10/23/18
Expiration Date: 01/31/20

Hardware & Software Requirements

To access activities, users will need:

  • A computer with an internet connection
  • An HTML5 compliant web browser or Internet Explorer 8 (and higher)

Copyright © PIM and DKBmed.

Your current email is:

To update your email address, please contact us at info@dkbmed.com.